Monte Rosa Therapeutics
GLUE
190 hedge funds and large institutions have $1.43B invested in Monte Rosa Therapeutics in 2026 Q1 according to their latest regulatory filings, with 51 funds opening new positions, 84 increasing their positions, 41 reducing their positions, and 20 closing their positions.
203% more call options, than puts
Call options by funds: $4.21M | Put options by funds: $1.39M
155% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 20
105% more repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 41
41% more capital invested
Capital invested by funds: $1.01B → $1.43B (+$419M)
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
18% more funds holding
Funds holding: 161 → 190 (+29)
9.63% more ownership
Funds ownership: 99.02% → 108.66% (+9.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VPC
Vestal Point Capital
New York
|
+$54.1M |
| 2 |
B
Braidwell
Stamford,
Connecticut
|
+$43.2M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$30.6M |
| 4 |
American Century Companies
Kansas City,
Missouri
|
+$28.3M |
| 5 |
BlackRock
New York
|
+$27.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VVM
Versant Venture Management
San Francisco,
California
|
-$23M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.27M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$4.97M |
| 4 |
PL
Parkwood LLC
Cleveland,
Ohio
|
-$3.88M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$3.24M |
GLUE Hedge Fund Activity: Q1 2026 in Review
190 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Monte Rosa Therapeutics (GLUE) for Q1 2026, worth a combined $1.43B — up 41% from $1.01B a quarter earlier.
Buyers outnumbered sellers: 51 funds opened new GLUE positions and 20 closed out — a net gain of 31 holders — while 84 added to existing stakes and 41 trimmed.
The largest buyer was Vestal Point Capital, adding an estimated $54.1M. The largest seller was Versant Venture Management, cutting an estimated $23M.
- 190 institutional investors held Monte Rosa Therapeutics (GLUE) as of Q1 2026, up from 161 in Q4 2025.
- Funds reported $1.43B of Monte Rosa Therapeutics stock for Q1 2026, up 41% quarter-over-quarter.
- 51 funds opened new Monte Rosa Therapeutics positions in Q1 2026 and 20 closed out, a net change of +31 holders.
- The largest Monte Rosa Therapeutics buyer in Q1 2026 was Vestal Point Capital, an estimated $54.1M added.
- The largest Monte Rosa Therapeutics seller in Q1 2026 was Versant Venture Management, an estimated $23M sold.
Based on aggregated 13F filings for Q1 2026.